Bachelor's degree in life sciences or related field; advanced degrees preferred., At least 12 years of experience in clinical operations within biotech or pharmaceutical industries., Proven leadership experience managing clinical programs and teams., Strong knowledge of regulatory requirements and clinical trial systems..
Key responsibilities:
Lead and oversee multiple clinical development programs from early to pivotal trials.
Manage all aspects of clinical trial operations, including protocol development and site management.
Coordinate with internal teams and external vendors to ensure seamless trial execution.
Ensure compliance with regulatory standards and lead process improvements.
Report this Job
Help us maintain the quality of our job listings. If you find any issues
with this job post, please let us know. Select the reason you're reporting
this job:
BlueRock Therapeutics is a leading engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. BlueRock Therapeutics’ cell+gene platform harnesses the power of cells to create new medicines for neurology, cardiology, and immunology indications.
BlueRock Therapeutics’ cell differentiation technology recapitulates the cell’s developmental biology to produce authentic cell therapies, which are further engineered for additional function. Utilizing these cell therapies to replace damaged or degenerated tissue brings the potential to restore or regenerate lost function.
BlueRock’s culture is defined by scientific innovation, the highest ethical standards and an urgency to bring transformative treatments to all who would benefit. The company strives to be a top employer of scientific talent, empowering every member of the team to make meaningful and lasting contributions to the burgeoning field of regenerative medicine.
Become a BlueRocker! We are expanding our BlueRock team at all locations. Contact us via LinkedIn or our website to learn about rewarding career opportunities.
BlueRock Therapeutics LP is a clinical stage cell therapy harnessing the power of cell therapy to create a pipeline of new medicines for people suffering from neurological and ophthalmic diseases. Two of our novel investigational cell therapies, bemdaneprocel (BRTDA01) for the treatment of Parkinson’s disease and OpCT001 for the treatment of primary photoreceptor diseases are clinical stage programs. BlueRock was founded in 2016 as a joint venture of Versant Ventures and Leaps by Bayer. Our culture is defined by the courage to persist regardless of the challenge, the urgency to transform medicine and deliver hope, integrity guided by mission, and communitymindedness with the understanding that we are all part of something bigger than ourselves.
What Are We Doing?
Our foundational science harnesses the ability to create and then direct the differentiation of universal pluripotent stem cells into authentic, functional cells that can be used as allogeneic cellular therapies to treat a broad array of diseases. We can also further engineer these cells, enabling them to produce enzymes, antibodies, and other proteins for additional therapeutic benefit.
We are passionate about delivering on the promise of cellular and gene therapy, shaping the future of cellular medicine, and delivering new therapies to millions of patients with treatment options.
We are seeking individuals who are collaborative, thrive in a fun and dynamic culture, and are steadfast in the commitment to advance cuttingedge cellular therapies to impact patients’ lives.
Our Pipeline Vision:
Neurology:
BlueRock is advancing an innovative pipeline of cell therapies in neurology, focused on addressing the urgent needs of patients with neurodegenerative and neurological disorders. Our lead neurology program, bemdaneprocel (DA01), is a firstinclass, allogeneic cell therapy designed to replace lost dopaminergic neurons in patients with Parkinson’s disease. This program is currently in phase 3 development with the exPDite2 clinical trial ongoing in the US, Canada, and Australia. Additional neurology pipeline assets, including DA02 and MG0X, are in research phase targeting other highimpact neurological conditions.Our goal is to restore function, slow or halt disease progression, and transform the standard of care for patients with debilitating neurological diseases.